Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.

ABSTRACT: Tocilizumab has been reported to attenuate the "cytokine storm" in COVID-19 patients. We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment. We conducted a randomized, controlled, open-label multicenter trial among COVID-19 patients. The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone. The cure rate, changes of oxygen saturation and interference, and inflammation biomarkers were observed. Thirty-three patients were randomized to the tocilizumab group, and 32 patients to the control group. The cure rate in the tocilizumab group was higher than that in the control group, but the difference was not statistically sign

SUBMITTER: Wang D 

PROVIDER: S-EPMC7940448 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature